{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T02:50:54Z","timestamp":1790391054530,"version":"4.1.0"},"reference-count":12,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2014,4,7]],"date-time":"2014-04-07T00:00:00Z","timestamp":1396828800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Int J of Rheum Dis"],"published-print":{"date-parts":[[2017,12]]},"abstract":"Abstract<\/jats:title>Aim<\/jats:title>Colchicine prophylaxis is the single most important factor in ameliorating familial Mediterranean fever (FMF<\/jats:styled-content>) for the prevention of both attacks and secondary amyloidosis. The aim of the present study was to evaluate the exact proportion of those patients who do not respond to colchicine and to characterize their demographic, sociodemographic and clinical aspects.<\/jats:p><\/jats:sec>Methods<\/jats:title>One hundred and eight patients with FMF<\/jats:styled-content> were included in our study. The demographic (age, gender), socioeconomic (education level, employment status, economic income level) and clinical features (age at onset of FMF<\/jats:styled-content>, age at FMF<\/jats:styled-content> diagnosis, family history of FMF<\/jats:styled-content>, mean duration of colchicine use and mean daily colchicine dose) of the patients were evaluated. The patients unresponsive to colchicine therapy, according to their statements, were recorded. Also with another question, patients\u2019 routine colchicine\u2010consuming habits were elucidated in a self\u2010answering format. \u2018Non\u2010responders\u2019 were defined as patients who experienced FMF<\/jats:styled-content> attacks at a frequency greater than once every 3\u00a0months despite treatment with 2\u00a0mg colchicine daily. Data were analyzed with the chi\u2010square test and Fisher's exact test.<\/jats:p><\/jats:sec>Results<\/jats:title>There were 50 female and 58 male patients with a mean age of 42.4\u00a0\u00b1\u00a011.3\u00a0years. The mean age at FMF<\/jats:styled-content> onset and at FMF<\/jats:styled-content> diagnosis were 14.3\u00a0\u00b1\u00a010.5 and 19.1\u00a0\u00b1\u00a012.9\u00a0years, respectively. Sixteen percent of the patients defined themselves as \u2018suffering from attacks in spite of regular colchicine\u2019. Irregular colchicine usage was determined in 11% of the patients who were considered as \u2018unresponsive to colchicine therapy\u2019 according to their statements. In spite of regular colchicine regimen, attacks were present in 5% of the patients in our study. Although there was no difference in demographic and clinical aspects, patients with irregular colchicine usage were found to be from lower socioeconomic backgrounds, had less education and more unemployment (P\u00a0<\/jats:italic><\u00a0<\/jats:italic>0.001).<\/jats:p><\/jats:sec>Conclusion<\/jats:title>Regular colchicine usage anamnesis may be misleading in the first evaluation and this risk seems to be higher in patients from lower socioeconomic background. Routine colchicine\u2010consuming habits should be detailed in patients with FMF<\/jats:styled-content> before claiming its failure.<\/jats:p><\/jats:sec>","DOI":"10.1111\/1756-185x.12374","type":"journal-article","created":{"date-parts":[[2014,4,7]],"date-time":"2014-04-07T08:02:39Z","timestamp":1396857759000},"page":"2118-2121","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Non\u2010response to colchicine in familial Mediterranean fever should be identified accurately"],"prefix":"10.1111","volume":"20","author":[{"given":"Meltem A.","family":"Melikoglu","sequence":"first","affiliation":[{"name":"Departments of Rheumatology Faculty of Medicine Ataturk University Erzurum Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazim","family":"Senel","sequence":"additional","affiliation":[{"name":"Physical Medicine and Rehabilitation Faculty of Medicine Ataturk University Erzurum Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2014,4,7]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1053\/S0049-0172(03)00137-9"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.3109\/0886022X.2011.605980"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00431-007-0547-3"},{"key":"e_1_2_6_5_1","first-page":"49","article-title":"Non\u2010response to colchicine in FMF\u2013definition, causes and suggested solutions","volume":"2","author":"Ben\u2010Chetrit E","year":"2008","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_2_6_6_1","first-page":"1540","article-title":"Association of drug transporter gene ABCB1 (MDR1) 3435C to T polymorphism with colchicine response in familial Mediterranean fever","volume":"34","author":"Tufan A","year":"2007","journal-title":"J Rheumatol"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780401023"},{"key":"e_1_2_6_8_1","first-page":"43","article-title":"Successful treatment of familial Mediterranean fever attacks with thalidomide in a colchicine\u2010resistant patient","volume":"20","author":"Seyahi E","year":"2002","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_2_6_9_1","first-page":"99","article-title":"Treatment options in colchicine resistant familial Mediterranean fever patients: thalidomide and etanercept as adjunctive agents","volume":"24","author":"Seyahi E","year":"2006","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-005-1122-9"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2008.04.001"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1067\/mcp.2003.1"},{"key":"e_1_2_6_13_1","first-page":"1278","article-title":"Medication adherence among patients in a chronic disease clinic","volume":"33","author":"Tourkmani AM","year":"2012","journal-title":"Saudi Med J"}],"container-title":["International Journal of Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2F1756-185X.12374","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2F1756-185X.12374","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1756-185X.12374","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T16:31:54Z","timestamp":1695573114000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/1756-185X.12374"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,4,7]]},"references-count":12,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["10.1111\/1756-185X.12374"],"URL":"https:\/\/doi.org\/10.1111\/1756-185x.12374","archive":["Portico"],"relation":{},"ISSN":["1756-1841","1756-185X"],"issn-type":[{"value":"1756-1841","type":"print"},{"value":"1756-185X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,4,7]]},"assertion":[{"value":"2014-04-07","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}